Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 6/20 | 0.45 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5866874 | 1.00 | NPC1 (0.53) | NPC1RAB9ASMN1; SMN2TP53TSHR | |
| SCHEMBL5866864 | 0.87 | HTT (0.52) | NPC1RAB9ASMN1; SMN2TP53TSHR | |
| SCHEMBL5866876 | 0.77 | IDO1 (0.64) | NPC1RAB9ASMN1; SMN2TP53TSHR | |
| SCHEMBL7588273 | 0.70 | THRB (0.42) | NPC1RAB9ASMN1; SMN2TP53TSHR | |
| SCHEMBL5866919 | 0.69 | MAPT (0.45) | NPC1RAB9ATP53TSHRMEN1 | |
| SCHEMBL5866920 | 0.69 | MAPT (0.45) | NPC1RAB9ATP53TSHRMEN1 | |
| SCHEMBL5866890 | 0.69 | KCNQ2 (0.41) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL5866892 | 0.69 | KCNQ2 (0.41) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL5866924 | 0.67 | LMNA (0.79) | NPC1RAB9ASMN1; SMN2TP53TSHR | |
| SCHEMBL2773514 | 0.67 | KMT2A (0.68) | NPC1RAB9ASMN1; SMN2TP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7148259-B1 | Antibacterial agents | AMGEN INC. (US) | 2006-12-12 | — | — | US | disclosed |
| US-20060270651-A1 | ANTIBACTERIAL AGENTS | AMGEN INC. (US) | 2006-11-30 | — | — | US | disclosed |
| US-7053234-B2 | Antibacterial agents | AMGEN INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20040235911-A1 | hydroxyamidines; antibiotic resistance | TULARIK INC. | 2004-11-25 | — | — | US | disclosed |
| US-6780858-B2 | Antibacterial agents | TULARIK INC. | 2004-08-24 | — | — | US | disclosed |
| US-20020045749-A1 | Antibacterial agents | AMGEN INC. | 2002-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235911-A1 | hydroxyamidines; antibiotic resistance | HNMT, HDHD5, ABCC1 | NPC1 2881/4885RAB9A 941/4885SMN1; SMN2 2862/4885 |
| US-20060270651-A1 | ANTIBACTERIAL AGENTS | MRPL21, HDHD5, CLPP | NPC1 2994/4885RAB9A 1357/4885SMN1; SMN2 3304/4885 |
| US-20020045749-A1 | Antibacterial agents | MRPL21, HDHD5, CLPP | NPC1 2994/4885RAB9A 1357/4885SMN1; SMN2 3304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.